Clinical analysis of tenofovir combined with sorafenib in patients with hepatitis B-related intermediate to advanced primary liver cancer

  • Min Zhao The Second Hospital of Dalian Medical University
  • Fangcheng Zhao The Second Hospital of Dalian Medical University
DOI: https://doi.org/10.18686/aem.v11i3.253
Keywords: Tenofovir, Sorafenib, Hepatitis B, Primary liver cancer

Abstract

Aim：To investigate the clinical efficacy of tenofovir combined with sorafenib in the treatment of patients with hepatitis B-related intermediate to advanced primary liver cancer. Methods：Sixty patients with hepatitis B-related intermediate to advanced primary liver cancer admitted to our hospital between January 2021 and December 2021 were selected and divided into 30 cases each in the study group and the control group according to the random number table method, in which the control group was treated with sorafenib and the study group was treated with tenofovir on top of the control group. Finally, the liver function indexes and clinical efficacy of the two groups of patients were observed and compared. Results：The total effective rate of treatment in the study group was 83.33%, while the total effective rate of treatment in the control group was 46.67%, There was a significant difference (P < 0.05) between the two groups comparing, Liver function indexes such as TBIL, ALB, PT and AFP before treatment in the study group were not significantly different from those in the control group (P > 0.05)，there were significant differences in liver function indexes such as TBIL, ALB, PT and AFP after treatment compared with the control group (P < 0.05). Conclusion：The short-term clinical efficacy and safety of tenofovir in combination with sorafenib in the treatment of patients with hepatitis B-related intermediate to advanced primary liver cancer is remarkable and worthy of clinical application.

References

[1] Liu J, Hu SJ, Guo JY, et al, A comparative analysis of the clinical characteristics of hepatitis B virus associated cirrhotic liver cancer and non cirrhotic liver cancer [J] From Journal of Clinical Gastroenterology, 2022, 34 (02): 115-119.

[2] An XQ, Li Y, et al. A clinical observation on tenofovir combined with sorafenib in the treatment of patients with hepatitis B related advanced primary liver cancer [J] From Journal of practical Hepatology, 2021,24 (04): 600-602.

[3] Zhang XR, Li W, Correlation of serum AFP, VEGF and AFU levels with microvascular invasion in patients with hepatitis B-associated hepatocellular carcinoma [J]. From Laboratory Medicine and Clinics,2021,18(22):3294-3297.

[4] Wang HX, Yu ZJ, Liu JP, and Zhao WX, The correlation between TCM evidence and T lymphocytes and biochemical indicators in patients with HBV-related primary liver cancer[J]. From the Journal of Hainan Medical College, 2021, 27(22): 1692- 1697+1703.

[5] Tang M, Chen Q, Guo S, The detection of liver cancer patients with low serum viral load HBV-DNA hepatitis B related hepatocytes [J] From contemporary medicine, 2021,27 (23): 91-93.

[6] Hou J, Ye FS, Qiu SJ, and Song YM, The correlation analysis between hepatitis B virus DNA load and immune function in patients with hepatitis B primary liver cancer[J]. From Chinese and Foreign Medical,2021,40(17):15-17.
Published
2022-11-01
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Min Zhao

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.